source
- Neurosterix raises $105M Series B to advance oral M4 schizophrenia drug and adds former Karuna leadersNeurosterix, a spinout from Addex Therapeutics, announced a $105 million Series B financing. The round was led by RTW Investments with participation from GV, Janus Henderson Investors and others. A…
- FDA faces over 1,000 vacant positions as staffing shortage strains pharma oversightThe FDA currently has more than a thousand open jobs, reflecting a deep staffing shortfall that began after a large wave of departures last year. The agency lost 1,343 employees at its CBER and CD…